What is Summit Therapeutics's other commercial liabilities?

Summit Therapeutics (SMMT) reported other commercial liabilities of $44.32M in Q1 2026.

How has Summit Therapeutics's other commercial liabilities changed year-over-year?

Summit Therapeutics's other commercial liabilities increased by 109.2% year-over-year, from $21.19M to $44.32M.

What is the long-term trend for Summit Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Summit Therapeutics's other commercial liabilities has grown at a 57.8% compound annual growth rate (CAGR), from $3.28M to $32.1M.

Summit Therapeutics SMMT Other Commercial Liabilities

Other Commercial Liabilities at other companies

IncyteINCY

——

Roivant SciencesROIV

——

Jazz PharmaceuticalsJAZZ

——

Johnson & JohnsonJNJ

——

ModernaMRNA

——

Vertex PharmaceuticalsVRTX

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's other commercial liabilities?: Summit Therapeutics (SMMT) reported other commercial liabilities of $44.32M in Q1 2026.
How has Summit Therapeutics's other commercial liabilities changed year-over-year?: Summit Therapeutics's other commercial liabilities increased by 109.2% year-over-year, from $21.19M to $44.32M.
What is the long-term trend for Summit Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Summit Therapeutics's other commercial liabilities has grown at a 57.8% compound annual growth rate (CAGR), from $3.28M to $32.1M.